DNAH8 and hypertrophic cardiomyopathy: Mavacamten is a first-in-class, selective allosteric inhibitor of cardiac myosin adenosine triphosphatase (ATPase), developed primarily for the treatment of hypertrophic obstructive cardiomyopathy (HOCM) [1,2].